$1.6 Million NIH Cooperative Agreement Supports SIGA Broad Spectrum Antiviral Research

        Print
| Source: SIGA Technologies, Inc.

NEW YORK, Sept. 29, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced the receipt of a $1.6 million research project cooperative agreement from the National Institutes of Health ("NIH") to accelerate the development of its broad-spectrum antiviral candidates.

Funds for the agreement have been made available through the American Recovery and Reinvestment Act ("ARRA") of 2009, which supports projects that will stimulate the economy, create or retain jobs, and have the potential for making scientific progress within two years of funding.

Dr. Robert Allen, principal investigator at SIGA for this grant, commented, "Working to develop a safe and effective lead compound and advancing this project into a clinical trial is our goal. These funds will support our efforts to find targets of identified broad-spectrum compounds."

"We are grateful for the government's continued commitment to funding our broad spectrum antiviral program. The funding we will receive as part of the stimulus plan, combined with another government contract that we are currently negotiating, is important to the success of this program," said Dr. Eric Rose, SIGA's Chief Executive Officer.

Broad-spectrum antiviral candidates, including ST-669, were discovered as part of a high-throughput screening campaign conducted against multiple viruses in the Bunyavirus family. These compounds demonstrated potent antiviral activity in the laboratory with minimal cellular toxicity against viruses from multiple genera within the Bunyavirus family, and, in the case of ST-669, against viruses outside this family.

ST-669 is SIGA's lead broad-spectrum antiviral candidate compound for viruses in the Poxviridae, Filoviridae, Bunyaviridae, Arenaviridae, Flaviviridae, Togaviridae, Retroviridae, and Picornaviridae families.

This project is the subject of Award Number U01AI082108 from the National Institute of Allergy and Infectious Diseases ("NIAID"). The content of this press release is solely the responsibility of SIGA and does not necessarily represent the official views of the NIAID or the NIH.

SIGA-G

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's web site at http://www.siga.com/.

The SIGA Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4504

Forward-looking Statements

This press release contains or implies certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the continued development and possible eventual approval of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond SIGA's control. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (i) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (ii) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (iii) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (iv) SIGA may not be able to secure funding from anticipated government contracts and grants, (v) SIGA may not be able to secure or enforce sufficient legal rights in its products, including sufficient patent protection for its products, (vi) regulatory approval for SIGA's products may require further or additional testing that will delay or prevent approval, (vii) the Biomedical Advanced Research & Development Authority may not complete the procurement set forth in its solicitation for the acquisition of a smallpox antiviral for the strategic national stockpile, or may complete it on different terms; (viii) SIGA's proposed drug candidate for responding to any governmental solicitation for purchase may not meet the requirements of the solicitation; (ix) the volatile and competitive nature of the biotechnology industry may hamper SIGA's efforts, (x) changes in domestic and foreign economic and market conditions may adversely affect SIGA's ability to advance its research or its products, and (xi) changing federal, state and foreign regulation on SIGA's businesses may adversely affect SIGA's ability to advance its research or its products. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2008, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.

KCSA Strategic Communications
Todd Fromer
  212-896-1215
  
Marybeth Csaby
  212-896-1236